Synergy San Diego | Lemon Grove, CA

Research site

(Unclaimed)

Location

7922 Palm Street, Lemon Grove, California, United States of America

Site insights

Top conditions

Top treatments

SEP-363856

Cariprazine

KarXT

Rapastinel

Pimavanserin

RO6889450

Ralmitaront

BHV-7000

BI 425809

ABBV-932

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 45 total trials

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatme...

Active, not recruiting

Acute Migraine

Drug: Placebo

Drug: Elismetrep (K-304) Dose level 3

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Enrolling

Major Depressive Disorder

Drug: SP-624

Drug: Placebo

A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD).For any individual participant, th...

Enrolling

Alcohol Use Disorder

Drug: Mazdutide

Drug: Placebo

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely...

Enrolling

Schizophrenia

Drug: SEP-363856

Other: Placebo

An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

An Extension study to a clinical study that will continue to evaluate the effectiveness and safety of SEP-363856 in people with schizophrenia that sw...

Invitation-only

Schizophrenia

Drug: SEP-363856

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately t...

Enrolling

Generalized Anxiety Disorder (GAD)

Drug: Antidepressant Therapy (ADT)

Drug: ABBV-932